Anthony Adam Rosenberg
Chairman presso OCULIS HOLDING AG
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Anthony Adam Rosenberg is currently the Chief Executive Officer at TR Advisory Services GmbH since 2015.
He is also the Chairman at Oculis SA since 2018, Chairman at Cullinan Oncology, Inc. since 2017, Chairman at Oculis Holding AG since 2018, Independent Non-Executive Director at argenx SE since 2017, Director at SiO2 Medical Products, Inc., Director at Cullinan Mica Corp.
(Massachussetts), and Senior Advisor at Kurma Partners SA since 2022.
In his former positions, Mr. Rosenberg served as a Director at Idenix Pharmaceuticals LLC from 2009 to 2012 and again from 2012 to 2013.
He was also a Director at Genoptix, Inc., Independent Director at Radius Health, Inc. from 2015 to 2020, Director at Clinical Ink, Inc., Managing Director at MPM BioImpact, Inc. from 2015 to 2020, Director at TriNetX, LLC, Independent Director at Cullinan Oncology LLC from 2017 to 2020, Director at European Biotech Acquisition Corp., Director at Clinincal Ink, Inc., Head-Mergers, Acquisitions & Licensing at Novartis AG from 2012 to 2015, Global Head-Business Development & Licensing at Novartis Pharmaceuticals Corp.
from 2005 to 2012, and Member-Supervisory Board at iOmx Therapeutics AG.
He also served as Head-Mergers, Acquisitions & Licensing at Novartis International AG from 2013 to 2015.
Mr. Rosenberg obtained a graduate degree from the University of London and an undergraduate degree from the University of Leicester.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
OCULIS HOLDING AG
0.26% | 31/12/2023 | 96 670 ( 0.26% ) | 1 M $ | 31/03/2024 |
| 15/02/2024 | 45 002 ( 0.10% ) | 766 834 $ | 31/03/2024 | |
ARGEN-X SE
0.00% | 20/02/2024 | 450 ( 0.00% ) | 177 925 $ | 31/03/2024 |
Posizioni attive di Anthony Adam Rosenberg
| Società | Posizione | Inizio |
|---|---|---|
| ARGENX SE | Director/Board Member | 26/04/2017 |
| CULLINAN THERAPEUTICS, INC. | Chairman | 01/04/2020 |
| OCULIS HOLDING AG | Chairman | 03/03/2023 |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a private company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. | Director/Board Member | - |
Kurma Partners SA
 Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Consultant / Advisor | 07/03/2022 |
SiO2 Medical Products, Inc.
 SiO2 Medical Products, Inc. Medical SpecialtiesHealth Technology SiO2 Medical Products, Inc. manufactures pharmaceutical products. It offers vials, syringes, cartridges, microplates, blood tubes, and bioscience consumables. The company was founded by Robert Abrams in November 2011 and is headquartered in Auburn, AL. | Director/Board Member | - |
Oculis SA
 Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Chairman | 01/04/2018 |
TR Advisory Services GmbH
 TR Advisory Services GmbH Miscellaneous Commercial ServicesCommercial Services TR Advisory Services GmbH engages in the provision of consulting and related services that focus on life science. The company was founded on May 22, 2015 and is headquartered in Riehen, Switzerland. | Chief Executive Officer | 01/04/2015 |
Precedenti posizioni note di Anthony Adam Rosenberg
| Società | Posizione | Fine |
|---|---|---|
| RADIUS HEALTH, INC. | Director/Board Member | 31/12/2020 |
| ░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Anthony Adam Rosenberg
| University of London | Graduate Degree |
| University of Leicester | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 4 |
|---|---|
| NOVARTIS AG | Health Technology |
| ARGENX SE | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| OCULIS HOLDING AG | Health Technology |
| Aziende private | 17 |
|---|---|
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Genoptix, Inc.
 Genoptix, Inc. Medical SpecialtiesHealth Technology Genoptix, Inc. provides specialized oncology diagnostics services. It offers a range of customizable clinical trial, custom assay development and companion diagnostics development services. The company was founded in 1999 by Tina S. Nova and is headquartered in Carlsbad, CA. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Clinical Ink, Inc.
 Clinical Ink, Inc. Internet Software/ServicesTechnology Services Clinical Ink, Inc. provides electronic source solutions for clinical research sites. Its solutions include data management, monitoring, clinical sites and patient centric. The company was founded by Douglas E. Pierce Jr. and Tommy Littlejohn on July 19, 2006 and is headquartered in Winston-Salem, NC. | Technology Services |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Kurma Partners SA
Kurma Partners SA Investment ManagersFinance Kurma Partners SA (KP) is an independent venture capital firm founded in 2009 by Thierry Laugel. The firm is headquartered in Paris, France. | Finance |
SiO2 Medical Products, Inc.
SiO2 Medical Products, Inc. Medical SpecialtiesHealth Technology SiO2 Medical Products, Inc. manufactures pharmaceutical products. It offers vials, syringes, cartridges, microplates, blood tubes, and bioscience consumables. The company was founded by Robert Abrams in November 2011 and is headquartered in Auburn, AL. | Health Technology |
TriNetX, LLC
 TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Health Services |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Commercial Services |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Health Technology |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
TR Advisory Services GmbH
TR Advisory Services GmbH Miscellaneous Commercial ServicesCommercial Services TR Advisory Services GmbH engages in the provision of consulting and related services that focus on life science. The company was founded on May 22, 2015 and is headquartered in Riehen, Switzerland. | Commercial Services |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a private company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. | Health Technology |
European Biotech Acquisition Corp.
 European Biotech Acquisition Corp. Financial ConglomeratesFinance European Biotech Acquisition Corp. is a blank check company which was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on January 8, 2021 and is headquartered in Lausanne, Switzerland. | Finance |
| Clinincal Ink, Inc. |
- Borsa valori
- Insiders
- Anthony Adam Rosenberg
